271 related articles for article (PubMed ID: 20161708)
1. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.
Shehadeh LA; Yu K; Wang L; Guevara A; Singer C; Vance J; Papapetropoulos S
PLoS One; 2010 Feb; 5(2):e9104. PubMed ID: 20161708
[TBL] [Abstract][Full Text] [Related]
2. A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson's patients is associated with the early stage onset of disease.
Fazeli S; Motovali-Bashi M; Peymani M; Hashemi MS; Etemadifar M; Nasr-Esfahani MH; Ghaedi K
PLoS One; 2020; 15(11):e0240855. PubMed ID: 33171483
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA and alternative splicing modulations in Parkinson's leukocytes identified by RNA sequencing.
Soreq L; Guffanti A; Salomonis N; Simchovitz A; Israel Z; Bergman H; Soreq H
PLoS Comput Biol; 2014 Mar; 10(3):e1003517. PubMed ID: 24651478
[TBL] [Abstract][Full Text] [Related]
4. Exon arrays reveal alternative splicing aberrations in Parkinson's disease leukocytes.
Soreq L; Bergman H; Israel Z; Soreq H
Neurodegener Dis; 2012; 10(1-4):203-6. PubMed ID: 22156489
[TBL] [Abstract][Full Text] [Related]
5. A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition.
Tomsic J; He H; Akagi K; Liyanarachchi S; Pan Q; Bertani B; Nagy R; Symer DE; Blencowe BJ; de la Chapelle A
Sci Rep; 2015 Jul; 5():10566. PubMed ID: 26135620
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of splice variant and wild-type parkin in sporadic Parkinson's disease.
Tan EK; Shen H; Tan JM; Lim KL; Fook-Chong S; Hu WP; Paterson MC; Chandran VR; Yew K; Tan C; Yuen Y; Pavanni R; Wong MC; Puvan K; Zhao Y
Neurogenetics; 2005 Dec; 6(4):179-84. PubMed ID: 16086186
[TBL] [Abstract][Full Text] [Related]
7. SRRM2 organizes splicing condensates to regulate alternative splicing.
Xu S; Lai SK; Sim DY; Ang WSL; Li HY; Roca X
Nucleic Acids Res; 2022 Aug; 50(15):8599-8614. PubMed ID: 35929045
[TBL] [Abstract][Full Text] [Related]
8. Aberrant alternative splicing events in Parkinson's disease.
Fu RH; Liu SP; Huang SJ; Chen HJ; Chen PR; Lin YH; Ho YC; Chang WL; Tsai CH; Shyu WC; Lin SZ
Cell Transplant; 2013; 22(4):653-61. PubMed ID: 23127794
[TBL] [Abstract][Full Text] [Related]
9. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death.
Bossers K; Meerhoff G; Balesar R; van Dongen JW; Kruse CG; Swaab DF; Verhaagen J
Brain Pathol; 2009 Jan; 19(1):91-107. PubMed ID: 18462474
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.
Simunovic F; Yi M; Wang Y; Macey L; Brown LT; Krichevsky AM; Andersen SL; Stephens RM; Benes FM; Sonntag KC
Brain; 2009 Jul; 132(Pt 7):1795-809. PubMed ID: 19052140
[TBL] [Abstract][Full Text] [Related]
11. Gene expression and isoform variation analysis using Affymetrix Exon Arrays.
Bemmo A; Benovoy D; Kwan T; Gaffney DJ; Jensen RV; Majewski J
BMC Genomics; 2008 Nov; 9():529. PubMed ID: 18990248
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
Hauser MA; Li YJ; Xu H; Noureddine MA; Shao YS; Gullans SR; Scherzer CR; Jensen RV; McLaurin AC; Gibson JR; Scott BL; Jewett RM; Stenger JE; Schmechel DE; Hulette CM; Vance JM
Arch Neurol; 2005 Jun; 62(6):917-21. PubMed ID: 15956162
[TBL] [Abstract][Full Text] [Related]
13. An Integrated Network Analysis of mRNA and Gene Expression Profiles in Parkinson's Disease.
Wang Y; Wang Z
Med Sci Monit; 2020 Mar; 26():e920846. PubMed ID: 32210219
[TBL] [Abstract][Full Text] [Related]
14. Silencing of long noncoding RNA SRRM2-AS exerts suppressive effects on angiogenesis in nasopharyngeal carcinoma via activating MYLK-mediated cGMP-PKG signaling pathway.
Chen S; Lv L; Zhan Z; Wang X; You Z; Luo X; You H
J Cell Physiol; 2020 Nov; 235(11):7757-7768. PubMed ID: 31742692
[TBL] [Abstract][Full Text] [Related]
15. Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients.
Potashkin JA; Santiago JA; Ravina BM; Watts A; Leontovich AA
PLoS One; 2012; 7(8):e43595. PubMed ID: 22952715
[TBL] [Abstract][Full Text] [Related]
16. SRRM2 splicing factor modulates cell fate in early development.
Carvalho S; Zea-Redondo L; Tang TCC; Stachel-Braum P; Miller D; Caldas P; Kukalev A; Diecke S; Grosswendt S; Grosso AR; Pombo A
Biol Open; 2024 Apr; 13(4):. PubMed ID: 38656788
[TBL] [Abstract][Full Text] [Related]
17. MADS+: discovery of differential splicing events from Affymetrix exon junction array data.
Shen S; Warzecha CC; Carstens RP; Xing Y
Bioinformatics; 2010 Jan; 26(2):268-9. PubMed ID: 19933160
[TBL] [Abstract][Full Text] [Related]
18. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
[TBL] [Abstract][Full Text] [Related]
19. Melatonin MT1 and MT2 receptor expression in Parkinson's disease.
Adi N; Mash DC; Ali Y; Singer C; Shehadeh L; Papapetropoulos S
Med Sci Monit; 2010 Feb; 16(2):BR61-7. PubMed ID: 20110911
[TBL] [Abstract][Full Text] [Related]
20. Implementation of exon arrays: alternative splicing during T-cell proliferation as determined by whole genome analysis.
Whistler T; Chiang CF; Lonergan W; Hollier M; Unger ER
BMC Genomics; 2010 Sep; 11():496. PubMed ID: 20840771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
